ClinicalTrials.gg
Not yet recruitingNCT07418502NeoMATCHUpdated Feb 18, 2026

Pressure Targeting During High Flow Therapy in Premature Infants

A Phase 2 interventional study of Pressure Targeted High Flow and CPAP in Preterm Infants, Respiratory Distress Syndrome (Neonatal) and BPD - Bronchopulmonary Dysplasia, sponsored by University of Texas at Austin. Not yet recruiting at 2 sites in United States. Open to participants aged 7 Days to 40 Weeks. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by University of Texas at Austin · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
7 Days to 40 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Pulmonary Atelectasis with a site in United States — 11 open to participants now, 11 under way, 1 of them phase 3. Pulmonary Atelectasis · United States.

Planned enrollment
15th of 37
78 · median 40
Started
2026
with 3 others
Phase 2
Only one
of the 43
Primary completion
2027-08
later than 4 of 10 live
Registered
41st of 43
by date

Among the 43 studies in Pulmonary Atelectasis with a site in United States, this one is the 15th largest by planned enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2026, is the only one in phase 2, reaches primary completion later than 4 of the 10 other live ones, and was the 41st registered.

Pulmonary Atelectasis

378 studies on the registry are indexed under Pulmonary Atelectasis; 91 are open to participants now.

Browse Pulmonary Atelectasis studies →

Open to participants now

11 of the 43 studies in Pulmonary Atelectasis with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Pulmonary Atelectasis studies recruiting now, 20 (39%) set no upper age limit and 23 (45%) stop at 75 or younger; 24 take children under 18; 2 take healthy volunteers.

This study: 7 Days to 40 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Pulmonary Atelectasis with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to see if a new approach to breathing support ('Pressure Targeted High Flow') is as effective as standard of care ('Continuous Positive Airway Pressure') in prematurely born infants. It will also learn about the effect of these types of breathing support on infant comfort and impact on staffing. The main question it aims to answer is:

Does Pressure Targeted High Flow provide enough support in premature infants?

Participants will:

Take spend 24 hours supported by Pressure Targeted High Flow and 24 hours supported by CPAP. During this time their breathing rate, oxygen requirement and other markers of comfort will be monitored.

03

Conditions studied

  • Preterm Infants
  • Respiratory Distress Syndrome (Neonatal)
  • BPD - Bronchopulmonary Dysplasia

Keywords

  • preterm
  • CPAP
  • High Flow
04

Who can participate

Ages eligible
7 Days to 40 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Delivery at >24+0 weeks and ≤32+6 weeks of gestation
  • Postnatal age >7 days but \< 6 weeks old
  • Weight ≥1,000grams at the time of study
  • Receiving clinically prescribed CPAP at pressures of 5-8cm H2O
  • Requiring an FiO2 of ≤0.60

Exclusion criteria

Exclusion Criteria:

  • Chromosomal disorder (aneuploidy)
  • Presence of major congenital birth defect including airway anomalies, congenital diaphragmatic hernia or cardiac defects (other than patent foramen ovale and patent ductus arteriosus)
  • Prior pneumothorax
  • Infants in whom chance of survival is uncertain
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Other
    PTHF First

    PTHF prior to CPAP

    Procedure: Pressure Targeted High Flow

  • Other
    CPAP First

    CPAP prior to PTHF

    Procedure: CPAP

Interventions

  • ProcedurePressure Targeted High Flow

    High Flow Nasal Cannula therapy with Pressure monitoring to match delivered CPAP pressure

  • ProcedureCPAP

    Standard of care CPAP therapy

06

What researchers measure

Primary outcomes

  1. Failure of Support

    Failure of respiratory support as defined by increase in fraction of inspired oxygen (FiO2) of ≥0.10, a pH of ≤7.2 with a CO2 ≥60 mm Hg, an increase in transcutaneous CO2 of ≥15mmHg above baseline or ≥2 episodes of apnea requiring positive-pressure ventilation

    Time frame: 24 hours

Secondary outcomes

  1. Oxygenation

    ratio of mean SpO2 to FiO2

    Time frame: 24 hours

  2. Respiratory Rate

    Mean respiratory rate

    Time frame: 24 hours

  3. Infant comfort - NIPE

    Newborn Infant Parasympathetic Evaluation

    Time frame: 24 hours

  4. Infant Comfort - Parent

    Parental Questionnaire

    Time frame: 24 hours

  5. Resource Use

    Number of handling/repositioning episodes by nurse/respiratory therapist

    Time frame: 24 hours

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided — Happy to share IPD if a need arises

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Aug 2027, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Feb 18, 2026
StartEst.
May 1, 2026
Primary completionEst.
Aug 2027
CompletionEst.
Sep 2027
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07418502
Collaborators
Sharp Mary Birch Hospital for Women & Newborns
Responsible party
Alan Groves (Professor of Pediatrics, University of Texas at Austin) — Principal investigator
First posted
Feb 18, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Feb 18, 2026

Study contacts

Alan Groves
Contact
alan.groves@austin.utexas.edu
512 324 1085

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion